section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source
rheumatic_endocrine_relationships,description,,,,,value,风湿免疫疾病与内分泌系统疾病的复杂关联关系网络,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,bidirectional_interactions,bidirectional interactions,,,,hormones_affect_immunity,激素调节免疫系统功能和自身免疫疾病发生发展,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,bidirectional_interactions,bidirectional interactions,,,,immunity_affects_endocrine,免疫系统异常影响内分泌腺体功能和激素分泌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,bidirectional_interactions,bidirectional interactions,,,,shared_pathogenesis,共同的遗传易感性、环境触发因素和分子机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.source_id,RHEUM_001,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.hashimoto_thyroiditis.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.hashimoto_thyroiditis.prevalence,15-30%的1型糖尿病患者合并,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.hashimoto_thyroiditis.shared_mechanisms,HLA-DQ2/DQ8遗传易感性; Th1型免疫反应优势; 分子模拟机制; 调节性T细胞功能缺陷,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.hashimoto_thyroiditis.clinical_implications,需要定期监测甲状腺功能和抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.hashimoto_thyroiditis.screening_recommendations,诊断时及每年筛查TSH、抗TPO,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.graves_disease.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.graves_disease.prevalence,1-5%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.graves_disease.mechanism,共同的HLA易感基因和自身免疫机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.thyroid_diseases.graves_disease.management,甲亢可能加重糖尿病酮症酸中毒风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.adrenal_diseases.addison_disease.relationship_type,共病（APS-1/APS-2成分）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.adrenal_diseases.addison_disease.prevalence,罕见，多见于多腺体综合征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.adrenal_diseases.addison_disease.shared_antigens,21-羟化酶等共同自身抗原,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.adrenal_diseases.addison_disease.clinical_significance,增加低血糖和酮症酸中毒风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.parathyroid_diseases.hypoparathyroidism.relationship_type,共病（主要见于APS-1）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.parathyroid_diseases.hypoparathyroidism.mechanism,钙敏感受体自身抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,type_1_diabetes_relationships.target_diseases.parathyroid_diseases.hypoparathyroidism.clinical_impact,低钙血症影响胰岛素敏感性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.source_id,RHEUM_002,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_1_diabetes.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_1_diabetes.prevalence,甲状腺疾病患者中糖尿病发病率增加2-3倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_1_diabetes.mechanisms,共同HLA易感基因; 细胞免疫和体液免疫异常; 甲状腺激素影响胰岛素敏感性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_2_diabetes.relationship_type,关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_2_diabetes.mechanism,甲状腺功能减退导致胰岛素抵抗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.diabetes.type_2_diabetes.prevalence,甲减患者糖尿病风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.reproductive_endocrine.pcos.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.reproductive_endocrine.pcos.prevalence,PCOS患者甲状腺疾病发病率增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.reproductive_endocrine.pcos.mechanism,胰岛素抵抗和激素相互作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.reproductive_endocrine.infertility.relationship_type,因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.reproductive_endocrine.infertility.mechanism,甲状腺激素影响生殖轴功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.bone_metabolism.osteoporosis.relationship_type,继发性关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.bone_metabolism.osteoporosis.mechanism,长期甲状腺激素替代治疗影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.source_id,RHEUM_003,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.thyroid_disorders.relationship_type,多腺体综合征成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.thyroid_disorders.prevalence,70-80%的APS-2患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.thyroid_disorders.sequential_pattern,通常在Addison病诊断前后数年出现,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.relationship_type,APS-2核心成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.prevalence,52%的APS-2患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.clinical_challenge,肾上腺功能不全增加低血糖风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.gonadal_dysfunction.primary_hypogonadism.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.gonadal_dysfunction.primary_hypogonadism.mechanism,自身免疫性卵巢炎/睾丸炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.gonadal_dysfunction.primary_hypogonadism.impact,加重骨质疏松和代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.relationship_type,APS-1成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.prevalence,89-96%的APS-1患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.electrolyte_management,复杂的电解质平衡管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.source_id,RHEUM_004,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.prevalence,15-20%的SLE患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.mechanism,共同的自身免疫机制和遗传背景,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.diabetes_complications.insulin_resistance.relationship_type,继发性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.diabetes_complications.insulin_resistance.mechanism,慢性炎症和糖皮质激素治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.diabetes_complications.insulin_resistance.prevalence,25-50%的SLE患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.diabetes_complications.steroid_diabetes.relationship_type,药物相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.diabetes_complications.steroid_diabetes.mechanism,长期糖皮质激素治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.menstrual_disorders.relationship_type,直接影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.menstrual_disorders.mechanism,疾病活动和药物治疗影响HPG轴,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.pregnancy_complications.relationship_type,高风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.pregnancy_complications.complications,妊娠期糖尿病、甲状腺功能异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.bone_endocrine.osteoporosis.relationship_type,多因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.bone_endocrine.osteoporosis.mechanisms,疾病本身的炎症; 糖皮质激素治疗; 维生素D缺乏; 性激素缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.adrenal_function.secondary_adrenal_insufficiency.relationship_type,药物相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.adrenal_function.secondary_adrenal_insufficiency.mechanism,长期糖皮质激素治疗后HPA轴抑制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.source_id,RHEUM_005,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.prevalence,RA患者糖尿病风险增加1.5-2倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.mechanisms,慢性炎症导致胰岛素抵抗; 糖皮质激素和其他药物治疗; 活动减少和肥胖,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.thyroid_disorders.hypothyroidism.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.thyroid_disorders.hypothyroidism.prevalence,10-15%的RA患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.thyroid_disorders.hypothyroidism.mechanism,共同的自身免疫背景,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.relationship_type,多重机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.prevalence,30-50%的RA患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.mechanisms,炎性细胞因子影响骨重建; 糖皮质激素治疗; 活动受限; 维生素D缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.reproductive_health.fertility_issues.relationship_type,治疗相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.reproductive_health.fertility_issues.mechanism,MTX等药物对生殖功能的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.adrenal_function.hpa_axis_dysfunction.relationship_type,疾病相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.adrenal_function.hpa_axis_dysfunction.mechanism,慢性炎症对HPA轴的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.source_id,RHEUM_006,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.relationship_type,高度共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.prevalence,30-50%的SS患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.thyroid_diseases.autoimmune_thyroiditis.mechanism,腺体自身免疫的共同病理机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.relationship_type,共病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.mechanism,胰岛自身免疫和腺体破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.reproductive_endocrine.ovarian_dysfunction.relationship_type,腺体受累,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.reproductive_endocrine.ovarian_dysfunction.mechanism,卵巢腺体自身免疫破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.bone_health.osteoporosis.relationship_type,多因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.bone_health.osteoporosis.mechanisms,慢性炎症; 维生素D吸收不良; 激素缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.source_id,RHEUM_007,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.hypoparathyroidism.prevalence,89-96%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.hypoparathyroidism.onset_age,5-10岁,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.hypoparathyroidism.relationship_type,核心成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.addison_disease.prevalence,72-100%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.addison_disease.onset_age,青少年期,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.addison_disease.relationship_type,核心成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.primary_hypogonadism.prevalence,60%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.primary_hypogonadism.relationship_type,主要成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.type_1_diabetes.prevalence,12-18%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.type_1_diabetes.relationship_type,次要成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.autoimmune_thyroiditis.prevalence,4-10%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.endocrine_manifestations.autoimmune_thyroiditis.relationship_type,次要成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.non_endocrine_associations.chronic_candidiasis,首发症状，与内分泌功能缺陷相互影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps1_relationships.non_endocrine_associations.ectodermal_dystrophy,发育异常影响生长发育,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.source_id,RHEUM_008,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.addison_disease.prevalence,100%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.addison_disease.relationship_type,定义性特征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.autoimmune_thyroid_disease.prevalence,70%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.autoimmune_thyroid_disease.relationship_type,核心成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.type_1_diabetes.prevalence,52%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.core_endocrine_triad.type_1_diabetes.relationship_type,核心成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.associated_conditions.primary_hypogonadism.prevalence,4-9%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.associated_conditions.primary_hypogonadism.relationship_type,伴发条件,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.associated_conditions.autoimmune_gastritis.prevalence,变异,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,aps2_relationships.associated_conditions.autoimmune_gastritis.relationship_type,消化内分泌关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.source_id,METAB_009/RHEUM_009,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.prevalence,糖尿病患者高尿酸血症发病率25-40%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.mechanisms,胰岛素抵抗促进肾小管尿酸重吸收; 高胰岛素血症激活URAT1转运体; 尿酸激活RAAS系统加重胰岛素抵抗; 氧化应激和慢性炎症共同通路,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.clinical_implications,血糖控制改善可降低血尿酸水平; 降尿酸治疗可能改善胰岛素敏感性; 需要监测药物相互作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.gestational_diabetes.relationship_type,关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.gestational_diabetes.mechanism,妊娠期胰岛素抵抗影响尿酸代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.gestational_diabetes.prevalence,GDM患者血尿酸水平显著升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hypothyroidism.relationship_type,因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hypothyroidism.prevalence,甲减患者高尿酸血症风险增加2-3倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hypothyroidism.mechanisms,基础代谢率下降影响嘌呤代谢; 肾血流量减少，尿酸清除率下降; 甲状腺激素调节尿酸转运体表达,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hypothyroidism.treatment_considerations,甲状腺激素替代治疗可改善高尿酸血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hyperthyroidism.relationship_type,保护性关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hyperthyroidism.mechanism,代谢率增加促进尿酸排泄,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.thyroid_disorders.hyperthyroidism.clinical_note,甲亢治疗后需要监测血尿酸水平变化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.metabolic_syndrome.core_component.relationship_type,组成成分,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.metabolic_syndrome.core_component.prevalence,代谢综合征患者高尿酸血症发病率60-70%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.metabolic_syndrome.core_component.pathophysiological_links,中心性肥胖与尿酸产生增加; 胰岛素抵抗核心机制; 血脂异常与尿酸代谢相互影响; 高血压与肾脏尿酸处理异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.cushings_syndrome.relationship_type,合并症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.cushings_syndrome.mechanism,皮质醇过多影响嘌呤代谢和肾功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.cushings_syndrome.prevalence,Cushing综合征患者高尿酸血症发病率增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.primary_aldosteronism.relationship_type,关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.primary_aldosteronism.mechanism,盐皮质激素过多影响肾小管功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.adrenal_disorders.primary_aldosteronism.clinical_impact,影响降尿酸药物疗效,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.pcos.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.pcos.prevalence,PCOS患者高尿酸血症发病率40-60%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.pcos.shared_mechanisms,胰岛素抵抗共同通路; 慢性低度炎症状态; 雄激素过多影响代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.pcos.therapeutic_implications,改善胰岛素敏感性可同时改善两种疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.menopause.relationship_type,关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.menopause.mechanism,雌激素缺乏影响尿酸代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.reproductive_endocrine.menopause.clinical_significance,绝经后女性高尿酸血症发病率显著上升,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.acromegaly.relationship_type,合并症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.acromegaly.mechanism,生长激素过多影响嘌呤代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.acromegaly.prevalence,肢端肥大症患者高尿酸血症发病率增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.growth_hormone_deficiency.relationship_type,关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.growth_hormone_deficiency.mechanism,GH缺乏影响肾功能和代谢率,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.growth_disorders.growth_hormone_deficiency.clinical_consideration,GH替代治疗对尿酸代谢的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.source_id,BONE_001/BONE_002/BONE_003,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.description,骨代谢疾病与内分泌系统的复杂相互作用关系,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.prevalence,1型糖尿病患者骨密度降低风险增加2-4倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.mechanisms,胰岛素缺乏影响成骨细胞功能; IGF-1水平下降影响骨形成; 高血糖产生糖基化终产物损伤骨基质; 慢性炎症状态影响骨重建,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.clinical_implications,年轻患者也需要骨密度筛查; 血糖控制对骨健康至关重要; 骨折愈合可能延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.bone_disease_patterns.osteoporosis,主要表现为骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.bone_disease_patterns.fracture_sites,椎体、髋部骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.relationship_type,复杂关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.paradox,骨密度可正常或增加但骨折风险仍增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.mechanisms,骨质量下降（微结构损伤）; 糖基化终产物影响胶原交联; 跌倒风险增加; 某些降糖药物影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.thiazolidinediones,噻唑烷二酮类增加骨折风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.sglt2_inhibitors,SGLT2抑制剂可能影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.insulin,胰岛素有益于骨健康,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.relationship_type,因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.prevalence,甲亢患者骨质疏松发病率增加5-10倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.mechanisms,甲状腺激素直接刺激破骨细胞活性; 骨转换加速，吸收>形成; 钙磷代谢紊乱; 维生素D代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.reversibility,甲亢控制后骨密度可部分恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.monitoring,需要骨密度定期监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.relationship_type,保护与风险并存,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.untreated_effects,未治疗甲减相对保护骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.treatment_effects,过度LT4替代可能增加骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.monitoring_importance,TSH维持在适宜范围,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.thyroid_cancer_survivors.tsh_suppression_therapy,TSH抑制治疗增加骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.thyroid_cancer_survivors.risk_stratification,根据复发风险平衡治疗获益与骨风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.relationship_type,直接因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.bone_disease,甲状旁腺性骨病的直接原因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.manifestations,骨质疏松（皮质骨>松质骨）; 骨膜下皮质骨吸收; 褐色瘤形成; 病理性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.surgical_benefit,甲状旁腺切除术后骨密度显著改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.relationship_type,治疗相关骨病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.mechanisms,PTH缺乏导致骨转换极度下降; 骨基质矿化异常; 皮质骨增厚但骨质量下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.treatment_challenges,传统治疗难以维持正常骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.secondary_hyperparathyroidism.ckd_mbd,慢性肾病骨矿物质代谢紊乱,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.secondary_hyperparathyroidism.vitamin_d_deficiency,维生素D缺乏引起继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.secondary_hyperparathyroidism.mixed_bone_disease,骨软化症与纤维囊性骨炎并存,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.relationship_type,强烈因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.prevalence,Cushing综合征患者骨质疏松发病率>50%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.mechanisms,皮质醇抑制成骨细胞分化和功能; 促进破骨细胞活性; 抑制肠道钙吸收; 影响性激素合成,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.rapid_onset,骨丢失可在短期内快速发生,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.fracture_risk,椎体骨折风险极高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.relationship_type,复杂关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.cortisol_deficiency,皮质醇缺乏对骨代谢的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.treatment_effects,糖皮质激素替代治疗的骨影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.monitoring,需要平衡激素替代与骨健康,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.relationship_type,强烈因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.estrogen_deficiency,雌激素缺乏是绝经后骨质疏松主因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.bone_loss_pattern,绝经后5-10年骨丢失加速,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.hrt_considerations,激素替代治疗的获益风险评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.male_hypogonadism.relationship_type,因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.male_hypogonadism.testosterone_effects,睾酮对男性骨健康的重要性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.male_hypogonadism.replacement_therapy,睾酮替代治疗改善骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.pcos.relationship_type,复杂关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.pcos.androgen_effects,雄激素过多对骨代谢的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.pcos.insulin_resistance,胰岛素抵抗与骨代谢相互作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.active_disease,活动期骨转换增加但骨密度可能正常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.post_treatment,治疗后骨密度可能下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.fracture_paradox,骨密度正常但骨折风险可能增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.gh_deficiency.relationship_type,因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.gh_deficiency.adult_ghd,成人生长激素缺乏导致骨密度下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.gh_deficiency.replacement_therapy,GH替代治疗改善骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.vitamin_d_deficiency.relationship_type,直接因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.vitamin_d_deficiency.primary_cause,骨软化症的主要病因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.vitamin_d_deficiency.secondary_effects,继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.vitamin_d_deficiency.global_prevalence,全球性维生素D缺乏问题,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.genetic_rickets.relationship_type,直接因果关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.genetic_rickets.hereditary_forms,遗传性维生素D代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.genetic_rickets.lifelong_management,需要终身专业管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.endocrinologist,内分泌激素平衡管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.orthopedist,骨科并发症处理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.rheumatologist,骨代谢专业评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.nutritionist,营养素缺乏纠正,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.prevention_strategies.hormonal_optimization,激素水平的优化管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.prevention_strategies.lifestyle_interventions,生活方式干预措施,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.prevention_strategies.pharmacological_prevention,药物预防策略,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.prevention_strategies.monitoring_protocols,规范化监测方案,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.underlying_endocrine,首先治疗潜在内分泌疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.bone_specific_therapy,必要时加用骨特异性治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.fracture_prevention,骨折预防为核心目标,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.quality_of_life,改善生活质量,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,source_id,NUTRI_001/NUTRI_002/NUTRI_003,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,description,营养代谢疾病与内分泌系统的综合关联关系,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.insulin_resistance.relationship_type,双向关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.insulin_resistance.mechanism,肥胖导致胰岛素抵抗，胰岛素抵抗促进脂肪堆积,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.insulin_resistance.clinical_implications,2型糖尿病发病风险增加10-20倍; 代谢综合征患病率>50%; 胰岛β细胞功能逐渐下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.thyroid_dysfunction.relationship_type,复杂关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.thyroid_dysfunction.subclinical_hypothyroidism,肥胖患者甲状腺功能减退患病率增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.thyroid_dysfunction.leptin_resistance,瘦素抵抗影响TSH分泌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.thyroid_dysfunction.weight_gain_cycle,甲减加重肥胖，肥胖影响甲状腺功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.reproductive_endocrine.pcos_relationship.prevalence,肥胖女性PCOS患病率增加3-5倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.reproductive_endocrine.pcos_relationship.mechanisms,胰岛素抵抗; 雄激素过多; 慢性炎症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.reproductive_endocrine.pcos_relationship.treatment_synergy,减重改善生殖内分泌功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.reproductive_endocrine.hypogonadism.male_obesity,内脏肥胖导致睾酮水平下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.obesity_endocrine_interactions.reproductive_endocrine.hypogonadism.aromatase_activity,脂肪组织芳香化酶活性增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.diabetes_progression.prediabetes_stage,代谢综合征是糖尿病前期重要标志,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.diabetes_progression.conversion_rate,年转化率5-10%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.diabetes_progression.prevention_strategies,生活方式干预有效预防,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.cardiovascular_endocrine.aldosterone_system,RAAS系统激活与代谢综合征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.cardiovascular_endocrine.cortisol_dysregulation,皮质醇节律异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.metabolic_syndrome_correlations.cardiovascular_endocrine.growth_hormone,生长激素分泌减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.parathyroid_interactions.secondary_hyperparathyroidism.mechanism,维生素D缺乏→PTH升高→骨代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.parathyroid_interactions.secondary_hyperparathyroidism.prevalence,维生素D缺乏患者PTH升高率>60%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.parathyroid_interactions.secondary_hyperparathyroidism.clinical_cascade,骨质疏松、肾结石、心律不齐风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.insulin_sensitivity.vitamin_d_insulin,维生素D受体存在于胰岛β细胞,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.insulin_sensitivity.glucose_metabolism,维生素D缺乏影响葡萄糖代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.insulin_sensitivity.diabetes_risk,血清25(OH)D每降低25nmol/L，糖尿病风险增加24%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.thyroid_interactions.autoimmune_thyroid,维生素D缺乏与自身免疫甲状腺病相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.thyroid_interactions.hashimoto_correlation,桥本甲状腺炎患者维生素D水平显著降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.obesity_treatment.endocrine_evaluation,筛查继发性肥胖内分泌原因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.obesity_treatment.hormonal_therapy,GLP-1激动剂双重获益,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.obesity_treatment.metabolic_surgery,减重手术改善多重内分泌异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.metabolic_syndrome_approach.multitarget_therapy,同时改善胰岛素敏感性、血脂、血压,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.metabolic_syndrome_approach.endocrine_optimization,甲状腺、性腺功能评估优化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.metabolic_syndrome_approach.lifestyle_medicine,营养、运动、行为综合干预,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.vitamin_d_supplementation.dosing_strategies,个体化剂量调整,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.vitamin_d_supplementation.monitoring_protocols,25(OH)D、PTH、血钙监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,therapeutic_implications.integrated_management.vitamin_d_supplementation.combination_therapy,与钙剂、其他维生素联用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,source_id,REPRO_001/REPRO_002/REPRO_003,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,description,生殖内分泌疾病与其他内分泌系统的复杂相互作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.insulin_resistance_axis.relationship_type,双向促进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.insulin_resistance_axis.mechanism,胰岛素抵抗↔高雄激素血症恶性循环,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.insulin_resistance_axis.clinical_implications,PCOS患者T2DM风险增加5-10倍; 代谢综合征患病率>50%; 心血管疾病风险显著增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.insulin_resistance_axis.therapeutic_targets,二甲双胍改善胰岛素抵抗和生殖功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.thyroid_interactions.hypothyroidism_prevalence,PCOS患者甲减患病率增加2-3倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.thyroid_interactions.mechanism,共同的代谢和免疫基础,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.thyroid_interactions.clinical_overlap,月经不调; 不孕; 代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.thyroid_interactions.screening_importance,PCOS患者需常规甲状腺功能筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.adrenal_hyperandrogenism.dhea_s_elevation,20-30%的PCOS患者DHEA-S升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.adrenal_hyperandrogenism.differential_diagnosis,需排除21-羟化酶缺陷,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.adrenal_hyperandrogenism.treatment_considerations,肾上腺来源雄激素的特异性治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.metabolic_syndrome_bidirectional.testosterone_metabolism,低睾酮促进内脏脂肪积累,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.metabolic_syndrome_bidirectional.insulin_resistance,胰岛素抵抗抑制睾酮合成,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.metabolic_syndrome_bidirectional.prevalence,代谢综合征男性中性腺功能减退率40%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.metabolic_syndrome_bidirectional.treatment_synergy,睾酮替代改善代谢参数,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.thyroid_function_effects.hypothyroidism_impact,甲减加重性腺功能减退,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.thyroid_function_effects.shbg_changes,甲状腺功能影响SHBG水平,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.thyroid_function_effects.combined_treatment,甲减治疗可部分改善性功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.growth_hormone_interactions.age_related_decline,GH和睾酮随年龄同步下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.growth_hormone_interactions.body_composition,共同影响肌肉量和脂肪分布,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.growth_hormone_interactions.bone_health,协同维护骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.autoimmune_clustering.aps_association,20%的POI患者合并其他自身免疫内分泌病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.autoimmune_clustering.common_targets,甲状腺; 肾上腺; 胰岛β细胞,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.autoimmune_clustering.screening_protocol,需系统性自身免疫内分泌评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.autoimmune_clustering.genetic_susceptibility,HLA-DRB1和DQA1关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.estrogen_deficiency,雌激素缺乏导致快速骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.pth_changes,PTH分泌和作用异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.vitamin_d_metabolism,1α-羟化酶活性下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.fracture_risk,骨折风险增加3-7倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.cardiovascular_endocrine.estrogen_protection_loss,失去雌激素心血管保护,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.cardiovascular_endocrine.lipid_metabolism,LDL升高，HDL下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.cardiovascular_endocrine.insulin_sensitivity,胰岛素敏感性下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.cardiovascular_endocrine.early_menopause_risks,心血管事件风险提前,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.insulin_resistance,妊娠期生理性胰岛素抵抗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.thyroid_adaptations,hCG对甲状腺的刺激作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.adrenal_modifications,皮质醇和醛固酮分泌增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.calcium_homeostasis,PTHrP分泌和钙代谢调节,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.lactation_hormonal_effects.prolactin_dominance,泌乳素抑制GnRH脉冲,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.lactation_hormonal_effects.hypothalamic_amenorrhea,哺乳期闭经机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.lactation_hormonal_effects.bone_calcium_mobilization,哺乳期骨钙动员,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.lactation_hormonal_effects.metabolic_adaptations,脂肪和葡萄糖代谢重塑,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.pcos_management.insulin_sensitizers,二甲双胍作为一线治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.pcos_management.ovulation_induction,来曲唑 vs 克罗米芬,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.pcos_management.antiandrogen_therapy,螺内酯、醋酸环丙孕酮,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.pcos_management.metabolic_monitoring,定期评估糖脂代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.male_hrt_protocols.testosterone_preparations,注射、凝胶、贴剂选择,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.male_hrt_protocols.monitoring_parameters,血红蛋白、PSA、肝功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.male_hrt_protocols.contraindications,前列腺癌、严重心力衰竭,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.male_hrt_protocols.fertility_preservation,hCG+FSH保留生育力,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.poi_hrt_strategies.estrogen_replacement,生理性雌激素替代,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.poi_hrt_strategies.progestin_protection,子宫内膜保护,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.poi_hrt_strategies.bone_health_focus,骨密度监测和干预,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.poi_hrt_strategies.cardiovascular_benefits,年轻女性HRT获益明确,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.diabetes_patients.thyroid_screening,诊断时和年度TSH、抗TPO筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.diabetes_patients.adrenal_screening,有症状时21-羟化酶抗体检测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.diabetes_patients.celiac_screening,腹部症状时抗组织转谷氨酰胺酶抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.thyroid_patients.diabetes_screening,年度空腹血糖或OGTT,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.thyroid_patients.autoantibody_panel,抗GAD、抗IA-2筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.thyroid_patients.other_autoimmune,根据症状筛查其他自身免疫疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.addison_patients.comprehensive_screening,诊断时全面多腺体功能评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.addison_patients.family_screening,一级亲属20%患病风险筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,screening_protocols.addison_patients.long_term_monitoring,终生监测新发自身免疫疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.drug_interactions.steroid_diabetes,糖皮质激素治疗需要密切监测血糖,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.drug_interactions.thyroid_adrenal,甲状腺激素替代前必须先纠正肾上腺功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.drug_interactions.immunosuppression_infections,免疫抑制治疗增加机会感染风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.monitoring_protocols.multi_gland_failure,多腺体功能衰竭的综合监测策略,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.monitoring_protocols.stress_response,应激状态下的激素调整方案,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.monitoring_protocols.pregnancy_management,妊娠期多种激素替代治疗管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,shared_biomarkers.genetic_markers,HLA基因型、非HLA易感基因多态性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,shared_biomarkers.immunological_markers,细胞因子谱、调节性T细胞功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,shared_biomarkers.metabolic_markers,代谢组学标志物、氧化应激指标,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,therapeutic_targets.immune_checkpoints,CTLA-4、PD-1通路调节,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,therapeutic_targets.cytokine_pathways,IL-17、TNF-α、干扰素通路,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,therapeutic_targets.metabolic_pathways,胰岛素敏感性、甲状腺激素信号,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,precision_medicine.genetic_risk_scoring,多基因风险评分预测疾病发生,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,precision_medicine.biomarker_guided_therapy,基于生物标志物的个体化治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
rheumatic_endocrine_relationships,research_implications,research implications,,,,precision_medicine.prevention_strategies,高风险人群的预防性干预,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
